Another analysis revealed an abrupt rise in the expression of PSMA on immunohistochemistry in contrast with prior benign PC, and its expression was observed in metastatic bone lesions in castrate-resistant prostate cancer (CRPC) (Schmittgen et al., 2003). This evidence concerns the gene FOLH1 and pachyonychia congenita.